Your browser is no longer supported. Please, upgrade your browser.
Settings
RARX Ra Pharmaceuticals, Inc. daily Stock Chart
RARX [NASD]
Ra Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.92 Insider Own0.60% Shs Outstand41.18M Perf Week-2.14%
Market Cap961.14M Forward P/E- EPS next Y-2.26 Insider Trans- Shs Float40.41M Perf Month7.81%
Income-67.50M PEG- EPS next Q-0.50 Inst Own98.20% Short Float5.26% Perf Quarter20.68%
Sales2.50M P/S384.46 EPS this Y14.60% Inst Trans6.25% Short Ratio4.52 Perf Half Y39.59%
Book/sh4.53 P/B5.15 EPS next Y-6.60% ROA-43.50% Target Price37.13 Perf Year285.15%
Cash/sh4.65 P/C5.02 EPS next 5Y- ROE-47.00% 52W Range5.96 - 27.68 Perf YTD28.24%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-15.75% Beta-
Dividend %- Quick Ratio20.10 Sales past 5Y- Gross Margin- 52W Low291.28% ATR1.40
Employees72 Current Ratio20.10 Sales Q/Q- Oper. Margin- RSI (14)52.33 Volatility5.75% 6.47%
OptionableYes Debt/Eq0.00 EPS Q/Q25.50% Profit Margin- Rel Volume0.35 Prev Close23.34
ShortableYes LT Debt/Eq0.00 EarningsMay 08 Payout- Avg Volume469.81K Price23.32
Recom1.50 SMA201.29% SMA500.78% SMA20028.23% Volume131,616 Change-0.09%
May-22-19Initiated SVB Leerink Outperform $33
Feb-08-19Initiated Stifel Buy $55
Oct-10-18Upgrade Raymond James Outperform → Strong Buy
Jul-20-18Initiated BMO Capital Markets Outperform $20
Jan-18-18Resumed Credit Suisse Outperform $16
Sep-15-17Initiated RBC Capital Mkts Outperform $21
May-14-19 07:00AM  Ra Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-09-19 07:19PM  Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX) Insider Monkey
07:00AM  Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update Business Wire
May-07-19 07:00AM  Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting Business Wire
Apr-24-19 06:30AM  Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress Business Wire
Apr-10-19 02:34PM  Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA Zacks
Apr-09-19 07:00AM  Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study Business Wire
Apr-01-19 04:05PM  Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting Business Wire -7.19%
Mar-07-19 07:31AM  Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update Business Wire +13.87%
Mar-04-19 07:00AM  Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference Business Wire
Feb-28-19 07:00AM  Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases Business Wire
Feb-25-19 03:25PM  5 Clinical-Stage Biotech Stocks to Buy InvestorPlace
Feb-21-19 07:00AM  Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference Business Wire +5.50%
Dec-20-18 12:27PM  Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX) Insider Monkey
Dec-11-18 06:32PM  Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire -9.70%
08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
Dec-10-18 04:32PM  Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today Motley Fool +7.05%
04:01PM  Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
03:26PM  Here's Why Ra Pharmaceuticals Inc. Is Soaring Today Motley Fool
01:54PM  Ra Pharma Shares Rally: What You Need To Know Benzinga
07:00AM  Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis Business Wire
Dec-06-18 07:30AM  Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck Business Wire
Nov-15-18 07:30AM  Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors Business Wire +12.93%
Nov-07-18 05:17PM  ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update Business Wire
Nov-06-18 07:30AM  Ra Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Sep-28-18 10:07AM  Can the Rally in Ra Pharmaceuticals (RARX) Shares Continue? Zacks
Sep-26-18 07:30AM  Ra Pharma Announces Positive Results from Phase 1b Pharmacokinetic Study of Zilucoplan (RA101495 SC) in Patients with Renal Impairment Business Wire +6.20%
Sep-25-18 04:05PM  Ra Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference Business Wire
07:30AM  Ra Pharma Elects Aoife M. Brennan, M.B., B.Ch., to Board of Directors Business Wire
Sep-05-18 07:30AM  Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program Business Wire
Aug-15-18 08:25AM  Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group Future Expectations, Projections Moving into 2018 GlobeNewswire -5.10%
Aug-08-18 07:15AM  Ra Pharmaceuticals Reports Second Quarter 2018 Financial Results and Announces Early Completion of Enrollment in gMG Phase 2 Program Business Wire +10.63%
Jun-15-18 07:00AM  Ra Pharmaceuticals Presents Data on Oral, Small Molecule Complement Inhibitors and Phase 2 RA101495 SC Program in PNH at the 23rd Congress of the European Hematology Association Business Wire
Jun-05-18 07:00AM  Ra Pharmaceuticals to Present at the 4th Congress of the European Academy of Neurology Business Wire
May-31-18 07:00AM  Ra Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference Business Wire
May-29-18 10:24AM  5 Clinical-Stage Biotech Stocks to Buy Under $10 InvestorPlace +6.17%
May-24-18 08:30AM  Research Report Identifies Brady, RA PHARMCTL INC, Sigma Designs, Teva Pharmaceutical Industries, Bridge, and BOK Financial with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-17-18 09:48AM  Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association Business Wire
May-09-18 04:30PM  Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update Business Wire
May-01-18 07:00AM  Ra Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference Business Wire
Apr-25-18 07:00AM  Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting Business Wire
Apr-18-18 07:00AM  Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer Business Wire
Apr-02-18 08:15AM  Recent Analysis Shows Jack Henry & Associates, Omnicell, Surgery Partners, Floor & Decor, NVE, and RA PHARMCTL INC Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-14-18 04:15PM  Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update Business Wire
Mar-07-18 07:00AM  Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference Business Wire
Mar-01-18 04:09PM  Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting Business Wire
Feb-28-18 07:00AM  Ra Pharma Supports 11th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases Business Wire
Feb-15-18 07:00AM  Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference Business Wire
Feb-14-18 09:13AM  Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock Business Wire
Feb-13-18 05:44PM  Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
Feb-12-18 07:00AM  Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria Business Wire
Jan-30-18 08:20AM  New Research: Key Drivers of Growth for VAREX IMAGING, DCP Midstream Partners, LP, Werner Enterprises, K12, RA PHARMCTL INC, and TOCAGEN INC Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-08-18 07:12AM  Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment Business Wire -5.70%
Dec-21-17 04:01PM  Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients Business Wire
Dec-07-17 07:12AM  Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference Business Wire
Dec-04-17 04:54PM  Why Ra Pharmaceuticals, Inc. Got Hammered Today Motley Fool -37.32%
07:00AM  Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria Business Wire
Nov-09-17 04:22PM  Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update Business Wire -6.56%
Oct-31-17 07:12AM  Ra Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Sep-20-17 07:12AM  Ra Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-12-17 04:56PM  Alexion Could Target Sage, Ra Pharma: Analyst TheStreet.com
Aug-09-17 04:18PM  Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update Business Wire
Jul-31-17 07:12AM  Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria Business Wire
Jul-19-17 04:05PM  Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis Business Wire
Jun-27-17 04:24PM  Here's Why Ra Pharmaceuticals Inc. Tumbled as Much as 32% Today Motley Fool -20.24%
07:00AM  Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH Business Wire
Jun-24-17 11:00AM  Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association Business Wire
Jun-21-17 04:30PM  Ra Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH Business Wire
Jun-06-17 08:09AM  Ra Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RARX-US : June 6, 2017 Capital Cube
May-31-17 07:12AM  Ra Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference Business Wire
May-18-17 06:12AM  Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association Business Wire
May-16-17 07:12AM  Ra Pharmaceuticals to Present at the UBS 2017 Global Healthcare Conference Business Wire
May-15-17 05:22PM  Ra Pharmaceuticals, Inc. Value Analysis (NASDAQ:RARX) : May 15, 2017 Capital Cube
May-12-17 08:54AM  Ra Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RARX-US : May 12, 2017 Capital Cube
May-11-17 04:20PM  Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update Business Wire
Apr-26-17 03:32PM  ETFs with exposure to Ra Pharmaceuticals, Inc. : April 26, 2017 Capital Cube
07:12AM  Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients Business Wire
Apr-06-17 08:06AM  Ra Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RARX-US : April 6, 2017 Capital Cube
Mar-21-17 09:52AM  Ra Pharmaceuticals, Inc. :RARX-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017 Capital Cube
Mar-10-17 01:04PM  RA PHARMACEUTICALS, INC. Financials
Mar-06-17 05:00PM  Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update Business Wire
04:11PM  RA PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-01-17 07:00AM  Ra Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference Business Wire
Feb-28-17 07:00AM  Ra Pharma Supports 10th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases Business Wire
Jan-27-17 07:00AM  Ra Pharma deploys IPO cash in quest to overtake a rare disease rival Alexion at bizjournals.com
07:00AM  Ra Pharma deploys IPO cash in quest to overtake a rare disease rival Alexion American City Business Journals
Jan-23-17 12:19PM  Ra Pharmaceuticals, Inc. Value Analysis (NASDAQ:RARX) : January 23, 2017 Capital Cube
Jan-20-17 08:29AM  Ra Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RARX-US : January 20, 2017 Capital Cube
Jan-04-17 02:55PM  Deloitte leads the way in Massachusetts IPO auditing work in 2016 at bizjournals.com
02:55PM  Deloitte leads the way in Massachusetts IPO auditing work in 2016 American City Business Journals
Dec-29-16 02:55PM  This Boston law firm won the most IPO work locally in 2016 at bizjournals.com
Dec-07-16 07:00AM  Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference Business Wire
Dec-02-16 04:05PM  RA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Nov-30-16 07:00AM  Ra Pharmaceuticals to Present Overview of RA101495 and Oral C5 Inhibitor at the International PNH Interest Group Annual Scientific Assembly Business Wire
Nov-29-16 04:15PM  Ra Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update Business Wire
04:10PM  RA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Nov-21-16 09:16AM  BMO Sets Outperform Rating, $26 Target On Ra Pharmaceuticals
06:57AM  Coverage initiated on RA Pharmaceuticals by Jefferies, SunTrust and Credit Suisse
Nov-17-16 07:00AM  Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria Business Wire
Oct-30-16 09:08AM  IPO Calendar for Coming Week Lists 2 Hopefuls
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah Rajeev M.DirectorDec 14Buy15.501,006,45215,600,0064,858,260Dec 14 06:14 PM
NEW ENTERPRISE ASSOCIATES 13 L10% OwnerDec 14Buy15.50645,1619,999,9966,135,234Dec 14 06:22 PM
RA CAPITAL MANAGEMENT, LLCDirectorDec 12Buy15.501,006,45215,600,0064,858,260Dec 14 06:17 PM